Hosted on MSN1d
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
followed by Keytruda as a single agent, for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy. The second ...
GlobalData on MSN1d
EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers
Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...
Does Adjuvant Therapy Prevent Cancer Recurrence?
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...